Health insurer Cigna to buy Express Scripts for about 54 billion dollars

Published On 2018-03-11 03:45 GMT   |   Update On 2018-03-11 03:45 GMT

U.S. health insurer Cigna Corp said it would buy pharmacy benefits manager Express Scripts Holding Co for about $54 billion, the latest deal in the sector aimed at tackling soaring healthcare costs.


The move follows the $69 billion mergers of insurer Aetna Inc and drugstore chain CVS Health Corp announced last December and highlights a sector-wide trend toward deals between companies that do not have directly overlapping operations.


The deals seek to lower healthcare costs by bringing under one roof pharmacy and medical claims and give the combined entities greater leverage in price negotiations with drugmakers.


Cigna's offer consists of $48.75 in cash and 0.2434 shares of stock of the combined company for each Express Scripts share, amounting to $96.03 per share. That represents a premium of nearly 31 percent to Express Scripts' Wednesday closing price.


Express Scripts shares were up 18.6 percent at $87.10, while Cigna shares were down 4.25 percent at $186.


The transaction is valued at $67 billion, including about $15 billion in Express Scripts' debt, the company said.


Pharmacy benefit managers administer prescription drug programs for health insurers, self-insured companies, and government agencies, negotiating deals with drug manufacturers, working with pharmacies and processing claims.


The CVS-Aetna deal was seen pressuring rival insurers, drugmakers, PBMs and retail pharmacies to consider mergers or switching partners to try to keep up with the potential healthcare cost savings or increase in profit margins.


The wave of consolidation in the sector also comes in the backdrop of a shifting landscape, including changes in the U.S. Affordable Care Act, rising drug prices and the threat of competition from Amazon.com Inc.


Leerink Partners analyst Ana Gupte said the deal may surprise investors given Cigna has said that they are satisfied with their PBM arrangement with UnitedHealth's Optum unit.


"It is possible that the threat of an Amazon entry into the healthcare and possibly the drug supply chain landscape, with the latest news of the Amazon/Berkshire Hathaway/JPMorgan employer coalition, has spurred Cigna and Express Scripts to tie the knot."


Amazon, Berkshire Hathaway Inc, and JPMorgan Chase & Co said in January they would form a company to cut health costs for hundreds of thousands of their employees.


DEAL DETAILS


After the deal closes, Cigna shareholders will own about 64 percent of the combined company and Express Scripts shareholders the rest.


Cigna intends to fund the cash portion of the deal through a combination of cash on hand, Express Scripts debt and new debt issuance. The company is expected to have a debt of about $41.1 billion after the deal closes.


The insurer said it obtained fully committed debt financing from Morgan Stanley Senior Funding and The Bank of Tokyo-Mitsubishi UFJ Ltd for the deal.


The combined company will be led by current Cigna Chief Executive Officer David Cordani.


The deal comes a year after Cigna's deal to buy Anthem Inc was blocked by antitrust regulators.


Morgan Stanley was the financial adviser to Cigna and Wachtell, Lipton, Rosen & Katz was the legal adviser. Paul, Weiss, Rifkind, Wharton & Garrison LLP is providing regulatory counsel.


Centerview Partners and Lazard Freres were financial advisers to Express Scripts, with Skadden, Arps, Slate, Meagher & Flom LLP serving as legal counsel and Holland & Knight LLP as regulatory counsel.


(Reporting by Ankur Banerjee; Additional reporting by Abinaya Vijayaraghavan, Philip George and Akshay Lodaya in Bengaluru; Editing by Saumyadeb Chakrabarty)

Article Source : REUTERS

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News